- Home
- PGZ vs PRLD Comparison
PGZ vs PRLD Comparison
Compare PGZ & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGZ | PRLD |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6M | 529.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PGZ | PRLD |
|---|---|---|
| Price | $9.13 | $4.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 17.8K | ★ 447.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 12.26% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $9.08 | $1.15 |
| 52 Week High | $10.60 | $6.83 |
Technical Indicators
Market Signals| Indicator | PGZ | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 15.98 | 37.04 |
| Support Level | N/A | $3.92 |
| Resistance Level | $10.32 | $4.69 |
| Average True Range (ATR) | 0.11 | 0.31 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 2.17 | 11.25 |
Price Performance
Historical ComparisonAbout PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Singapore, South Korea, British Virgin Islands and more.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.